Dr. Reddy's Laboratories growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+3.2%+11.0%
EBITDA−24.5%+0.5%
Net Income−27.4%−2.7%
EPS (adj.)−25.8%−2.4%
Total Assets+17.6%+21.6%
Total Equity+12.7%+18.0%
Free Cash Flow+52.4%−22.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

DRREDDY₹1,335.40

Dr. Reddy's Laboratories Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLALUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹1.12L Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+3.2+11.0
EBITDA-24.5+0.5
Net Income-27.4-2.7
EPS (adj.)-25.8-2.4
Total Assets+17.6+21.6
Total Equity+12.7+18.0
Free Cash Flow+52.4-22.9
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.